ASX Hot too!, page-446

Agree with you, @Phaedrus, that the company was juggling too many balls or dealing with too much uncertainty in December. I don’t like the level at which the CR was done, but people also don’t seem to realise or remember how much of a massive as well as crucial turnaround the company went through in the first quarter, in so many different ways. Could there have been less dilution? Perhaps, but I personally believe that the company might have been on its knees without the cap raise, in which case the “adaptation” of the FDA would have been completely futile. Instead, in a quick succession of moves, it got the ship righted.

Hand on heart, as a top 500 shareholder I can say I have applauded the management team’s moves in the last few months.